公开(公告)号：WO2023026246A1

公开(公告)日：2023-03-02

申请号：PCT/IB2022/058006

申请日：2022-08-26

Applicant: INTERNATIONAL BUSINESS MACHINES CORPORATION ,  IBM (CHINA) INVESTMENT COMPANY LTD. ,  IBM DEUTSCHLAND GMBH

Inventor： LUAN, Binquan ,  ZHANG, Leili ,  HUYNH, Tien

IPC: C07K16/10 ,  A61K39/215 ,  A61P11/00 ,  A61P31/14 ,  C07K14/165

Abstract: Provided are anti-binding proteins that can bind to CoV (e.g., SARS-CoV-2) variants. For example, one or more embodiments described herein can comprise an antigen-binding protein that can comprise a heavy chain variable region with an amino acid sequence that is a variant of SEQ ID NO:7. The amino acid sequence can comprise at least one amino acid substitution selected from the group consisting of : R50D, R50E, R50W, R50F, R50Y, R50L, R50V, R50I, R50Pho, I54D, I54E, I54F, I54Y, I54Pho, L55D, L55E, L55W, L55F, L55Y, and L55Pho.

公开(公告)号：WO2023025813A1

公开(公告)日：2023-03-02

申请号：PCT/EP2022/073498

申请日：2022-08-23

Applicant: INSTITUT PASTEUR

Inventor： LAFAYE, Pierre ,  ESCRIOU, Nicolas ,  FERNANDEZ, Ignacio ,  AYME, Gabriel ,  REY, Félix ,  GUARDADO CALVO, Pablo ,  GRANSAGNE, Marion ,  SCHWARTZ, Olivier ,  MARTIN, Annette

IPC: C07K16/10 ,  A61K39/215 ,  A61P31/14 ,  A61K39/00

Abstract: An isolated single domain VHH antibody that binds to the ACE2 receptor binding domain (RBD) of SARS-CoV-2 (SEQ ID NO: 28), wherein the isolated single domain VHH antibody comprises an amino acid sequence that is at least 70% identical to an amino acid sequence selected from the group consisting of SEQ ID NOS: 1 -4, 32, and 34.

公开(公告)号：WO2023025253A1

公开(公告)日：2023-03-02

申请号：PCT/CN2022/114867

申请日：2022-08-25

Applicant: 甘李药业股份有限公司

Inventor： 焦娇 ,  乔晶 ,  李若微 ,  刘耀辉 ,  王佳星 ,  王震 ,  秦汉 ,  马子跃 ,  王娇 ,  张铃 ,  车黎明 ,  田书苗 ,  王瑞雪 ,  闫伟欢 ,  姜雅婷

IPC: C07K16/10 ,  C12N15/13 ,  G01N33/569 ,  A61K39/42 ,  A61P31/14

Abstract: 提供对RSV病毒具有有效中和活性的抗体或其抗原结合片段。所提供的抗RSV病毒抗体或其抗原结合片段可以作为用于治疗或预防RSV感染或RSV感染相关症状的药物。所提供的RSV抗体经人源化改造后能够以高亲和力结合RSV-F蛋白，并且实验显示在针对RSV攻击提供保护方面表现出显著优于帕利珠单抗的效果。

公开(公告)号：WO2023008553A1

公开(公告)日：2023-02-02

申请号：PCT/JP2022/029274

申请日：2022-07-29

Applicant: 株式会社オーダーメードメディカルリサーチ ,  ＤＤサプライ株式会社

Inventor： 村上　康文 ,  秋山　弘匡 ,  柏葉　脩一郎 ,  岡部　洋子 ,  岡　英治 ,  福岡　聖之

IPC: C07K16/10 ,  A61K39/395 ,  A61P1/02 ,  A61P1/04 ,  A61P9/00 ,  A61P11/00 ,  A61P17/00 ,  A61P25/00 ,  A61P25/02 ,  A61P25/04 ,  A61P25/18 ,  A61P27/16 ,  A61P29/00 ,  A61P31/12 ,  A61P31/14 ,  A61P43/00 ,  C12N15/13 ,  C12N15/50 ,  C12P21/08

Abstract: 本発明は、変異型コロナウイルスのスパイクタンパク質のRBDとACE2との結合を中和する新規分子の提供を目的とする。本発明は、変異型コロナウイルスのスパイクタンパク質に結合するニワトリ抗体を提供する。

公开(公告)号：WO2023004431A2

公开(公告)日：2023-01-26

申请号：PCT/US2022/074075

申请日：2022-07-22

Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

Inventor： HO, David, D. ,  HUANG, Yaoxing ,  LIU, Lihong ,  NAIR, Manoj, S. ,  YU, Jian ,  IKETANI, Sho

IPC: A61K39/42 ,  A61P31/14 ,  C07K16/10 ,  C12N15/13 ,  C12N15/63 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2317/92

Abstract: The subject matter described herein relates to engineered monoclonal antibodies, derived from antibodies isolated from human patients, neutralizing a SARS-CoV-2 virus, its variants, or related coronaviruses.

公开(公告)号：WO2023283576A1

公开(公告)日：2023-01-12

申请号：PCT/US2022/073463

申请日：2022-07-06

Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Inventor： REAGAN, Erin, Kathleen ,  WEISSMAN, Drew

IPC: A61K39/29 ,  A61P31/14 ,  A61P37/04 ,  C07K16/10 ,  A61K31/7088 ,  C12N7/00 ,  G01N33/576

Abstract: There is an urgent need to develop a prophylactic HCV vaccine, and to determine if therapeutic vaccines can aid in the treatment of chronically infected patients. Described are compositions comprising a nucleoside-modified RNA molecules encoding a HCV p7 protein in combination with at least one additional HCV antigen, adjuvant, or a combination thereof, and their use for inducing an immune response against HCV.

公开(公告)号：WO2023283134A1

公开(公告)日：2023-01-12

申请号：PCT/US2022/035968

申请日：2022-07-01

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： MURPHY, Andrew ,  KYRATSOUS, Christos ,  BAUM, Alina ,  PETRO, Christopher

IPC: C07K16/10 ,  A61K39/215 ,  A61P31/14

Abstract: Described herein are methods and compositions for directing an antibody response in a subject away from one or more first epitopes of an antigen (e.g., immunodominant epitopes of a vaccine antigen) and towards one or more second epitopes of the antigen by administering one or more antibodies targeting the one or more first epitopes of the antigen.

公开(公告)号：WO2023275538A1

公开(公告)日：2023-01-05

申请号：PCT/GB2022/051663

申请日：2022-06-28

Applicant: DIOSYNVAX LTD ,  THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE ,  UNIVERSITÄT REGENSBURG

Inventor： VISHWANATH, Sneha ,  CARNELL, George ,  ASBACH, Benedikt ,  WAGNER, Ralf ,  KINSLEY, Rebecca ,  HEENEY, Jonathan, Luke ,  WELLS, David

IPC: C07K16/10 ,  A61P31/14

Abstract: Vaccines that induce a broadly neutralising immune response to protect against disease caused by beta-coronaviruses, especially beta-coronaviruses of the sarbecovirus and merbecovirus lineages, are described. The vaccines are provided by use of phylogenetically-, and epitope-optimised sarbecovirus and merbecovirus RBD subunits. The vaccines are provided as nucleic acid vaccines, either as separate polynucleotides, each encoding a different RBD subunit (or RBD dimer), or pieced together in a string as a single polynucleotide encoding all of the RBD subunits (or RBD dimers). The separate polynucleotides may be administered as a mixture together, co-administered, or administered sequentially in any order. Polynucleotides, polypeptides, vectors, cells, fusion proteins, pharmaceutical compositions, combined preparations, and their use as vaccines against viruses of the coronavirus family are described. Methods of inducing an immune response to, or immunising a subject against, a beta-coronavirus in a subject by administering an effective amount of a vaccine to the subject are also described.

公开(公告)号：WO2022271258A1

公开(公告)日：2022-12-29

申请号：PCT/US2022/024908

申请日：2022-04-14

Applicant: LA JOLLA INSTITUTE FOR IMMUNOLOGY

Inventor： SAPHIRE, Erica Ollmann ,  HASTIE, Kathryn ,  LANDERAS-BUENO, Sara ,  HARKINS, Stephanie

IPC: C07K16/10 ,  A61P31/14 ,  G01N33/569 ,  A61K39/00

Abstract: Compositions and methods are disclosed for diagnosing, treating, and/or preventing coronavirus infection and related pathologies. The compositions include antibodies having certain defined heavy and light chain sequences that recognize the coronavirus nucleoprotein or mutants thereof. In embodiments, the coronavirus is SARS-CoV-2

公开(公告)号：WO2022266235A1

公开(公告)日：2022-12-22

申请号：PCT/US2022/033651

申请日：2022-06-15

Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

Inventor： BRIESE, Thomas ,  LIPKIN, Walter, Ian ,  MISHRA, Nischay

IPC: C07K16/10 ,  C07K14/165 ,  A61P31/12

Abstract: The current disclosure provides for polypeptides, single domain antibodies, VHHs and nanobodies which bind to or are directed against the SARS-CoV-2 virus, more specifically the spike protein of the SARS-CoV-2 virus. The disclosed VHHs and nanobodies can comprise a sequence selected from the sequences listed in Table 1 (SEQ ID NOs: 1-60), and fragments, derivatives and homologues thereof. The disclosure further provides for compositions comprising the anti-SARS-CoV-2 polypeptides, single domain antibodies, VHHs and nanobodies, and methods of making and using such for treatment, prevention, detection and diagnosis.